Sangamo Therapeutics (SGMO) Earning Somewhat Positive Press Coverage, Report Shows
Media headlines about Sangamo Therapeutics (NASDAQ:SGMO) have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Sangamo Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 44.7271299486182 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Sangamo Therapeutics Announces Participation At Upcoming Investor And Industry Conferences (finance.yahoo.com)
- Sangamo Therapeutics (SGMO) Presents At Cantor Fitzgerald Global Healthcare Conference – Slideshow (seekingalpha.com)
- Head-To-Head Review: Radius Health (RDUS) & Sangamo Therapeutics (SGMO) (americanbankingnews.com)
- Sangamo Therapeutics, Inc. (SGMO) Receives Consensus Rating of “Hold” from Brokerages (americanbankingnews.com)
- Notable Buzzer: Sangamo Therapeutics, Inc. (SGMO) – Wall Street Morning (wallstreetmorning.com)
Shares of Sangamo Therapeutics (SGMO) opened at 15.00 on Friday. Sangamo Therapeutics has a 52 week low of $2.65 and a 52 week high of $15.30. The stock’s market cap is $1.25 billion. The stock’s 50 day moving average is $11.44 and its 200 day moving average is $7.79.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.06. The firm had revenue of $8.30 million for the quarter, compared to the consensus estimate of $5.82 million. Sangamo Therapeutics had a negative net margin of 151.35% and a negative return on equity of 31.34%. The business’s revenue was up 124.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.38) earnings per share. On average, equities analysts forecast that Sangamo Therapeutics will post ($0.82) EPS for the current year.
Several equities research analysts have commented on the stock. ValuEngine upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Piper Jaffray Companies set a $8.00 price objective on shares of Sangamo Therapeutics and gave the company a “hold” rating in a research note on Thursday, August 10th. BidaskClub lowered shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Friday, August 18th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $17.00 price objective on shares of Sangamo Therapeutics in a research note on Thursday, June 22nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $14.40.
In related news, Director William R. Ringo sold 31,000 shares of the stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $14.37, for a total transaction of $445,470.00. Following the transaction, the director now owns 31,800 shares in the company, valued at $456,966. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Curt A. Herberts III sold 11,474 shares of the stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $10.44, for a total transaction of $119,788.56. Following the transaction, the vice president now owns 23,991 shares in the company, valued at approximately $250,466.04. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,474 shares of company stock worth $940,259. 8.10% of the stock is owned by insiders.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.